Advertisement
Canada markets open in 5 minutes

  • S&P/TSX

    22,011.62
    +42.38 (+0.19%)
     

  • S&P 500

    5,116.17
    +16.21 (+0.32%)
     

  • DOW

    38,386.09
    +146.43 (+0.38%)
     

  • CAD/USD

    0.7283
    -0.0039 (-0.53%)
     

  • CRUDE OIL

    82.46
    -0.17 (-0.21%)
     

  • Bitcoin CAD

    86,000.88
    -925.06 (-1.06%)
     

  • CMC Crypto 200

    1,262.12
    -76.94 (-5.75%)
     

  • GOLD FUTURES

    2,317.00
    -40.70 (-1.73%)
     

  • RUSSELL 2000

    2,016.03
    +14.03 (+0.70%)
     

  • 10-Yr Bond

    4.6630
    +0.0490 (+1.06%)
     

  • NASDAQ futures

    17,837.75
    -66.50 (-0.37%)
     

  • VOLATILITY

    15.03
    +0.36 (+2.45%)
     

  • FTSE

    8,176.82
    +29.79 (+0.37%)
     

  • NIKKEI 225

    38,405.66
    +470.90 (+1.24%)
     

  • CAD/EUR

    0.6804
    -0.0020 (-0.29%)
     
MARKETS LIVE BLOG:

STOCK FUTURES HIT PAUSE WITH FED IN FOCUS, AMAZON EARNINGS ON DECK

Prospect of rate cuts has fallen dramatically since the start of 2024, helping drive up Treasury yields

Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?

Zacks Equity Research
·2 min read

Indivior PLC (INDV) shares rallied 5.6% in the last trading session to close at $22. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.9% loss over the past four weeks.

The sudden rise in the stock price can be attributed to the positive investor minsent regarding the company's early to mid-stage pipeline of innovative therapies to treat opiod and cannabis use disorders.

This company is expected to post quarterly earnings of $0.38 per share in its upcoming report, which represents a year-over-year change of -5%. Revenues are expected to be $300 million, up 18.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

ADVERTISEMENT

For Indivior, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on INDV going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Indivior is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, USANA Health Sciences (USNA), finished the last trading session 2.6% lower at $45.44. USNA has returned -0.3% over the past month.

For USANA Health , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.69. This represents a change of -27.4% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #4 (Sell).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Indivior PLC (INDV) : Free Stock Analysis Report

USANA Health Sciences, Inc. (USNA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research